Literature DB >> 12428935

Oral contraception: patterns of non-compliance. The Coraliance study.

E Aubeny1, M Buhler, J C Colau, E Vicaut, M Zadikian, M Childs.   

Abstract

OBJECTIVES: To determine the number of times women failed to take their oral contraceptive medication and their behavior in response to a missed pill. Another objective was to determine the potential benefit provided by a continuously administered oral contraceptive compared with an oral contraceptive involving a pill-free interval during a 6-month period.
METHODS: Healthy women were enrolled in a cohort study; their contraceptive practices were followed by their gynecologists. Data were collected at inclusion using cross-sectional method with retrospective data collection for the previous 6 months and, more specifically, on their previous or their current menstrual cycle. Women on the pill were asked to specify the number of times and precise time at which they missed one or more pills and what they did in response to missing a pill.
RESULTS: A total of 617 gynecologists enrolled and followed 3316 patients from six geographic areas throughout France. The mean age of patients was 30 years. Duration of oral contraceptive use was 8 years. During their previous cycle, 23% of women (n = 737) missed a pill at least once. Among women on the pill involving a treatment-free interval, 42% of instances of missing a pill occurred during the first week following the treatment-free interval. In response to missing a pill, patients read the product information leaflet (39%) or asked someone's advice (28%), mainly their gynecologist (63%) or their family physician (18%). Almost one-third of women did not take any specific measures.
CONCLUSIONS: Patients on a discontinuous oral contraceptive regimen tended to miss a pill during the first week of treatment. Prescription of a continuous regimen without a treatment-free interval may improve compliance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12428935

Source DB:  PubMed          Journal:  Eur J Contracept Reprod Health Care        ISSN: 1362-5187            Impact factor:   1.848


  7 in total

1.  Adherence with ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen supported by the use of a digital tablet dispenser with or without acoustic alarm: an open-label, randomized, multicenter study.

Authors:  Inka Wiegratz; Jörg Elliesen; Anna Maria Paoletti; Anja Walzer; Bodo Kirsch
Journal:  Int J Womens Health       Date:  2015-01-05

2.  Understanding the use of contextual cues: design implications for medication adherence technologies that support remembering.

Authors:  Katarzyna Stawarz; Marcela D Rodríguez; Anna L Cox; Ann Blandford
Journal:  Digit Health       Date:  2016-12-01

3.  Evaluation of factors associated with noncompliance in users of combined hormonal contraceptive methods: a cross-sectional study: results from the MIA study.

Authors:  Txantón Martínez-Astorquiza-Ortiz de Zarate; Teresa Díaz-Martín; Txantón Martínez-Astorquiza-Corral
Journal:  BMC Womens Health       Date:  2013-10-20       Impact factor: 2.809

Review 4.  Extended regimen combined oral contraception: A review of evolving concepts and acceptance by women and clinicians.

Authors:  Rossella E Nappi; Andrew M Kaunitz; Johannes Bitzer
Journal:  Eur J Contracept Reprod Health Care       Date:  2015-11-17       Impact factor: 1.848

5.  Adherence to a flexible extended regimen for oral hormonal contraception provided in blister packaging compared with an adherence-supporting digital tablet dispenser: historical comparison of data from two clinical studies.

Authors:  Jörg Elliesen; Dietmar Trummer
Journal:  Int J Womens Health       Date:  2016-08-09

Review 6.  Contraception for women with epilepsy: counseling, choices, and concerns.

Authors:  Arne Reimers
Journal:  Open Access J Contracept       Date:  2016-04-19

7.  Situation of Adolescent Contraceptive Use in Germany.

Authors:  Patricia G Oppelt; Christine Fahlbusch; Katharina Heusinger; Laura Lotz; Ralf Dittrich; Friederike Baier
Journal:  Geburtshilfe Frauenheilkd       Date:  2018-10-19       Impact factor: 2.915

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.